Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 6

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 8
Chunk 6
---
 July 2018 to December 2022. Mr. Hanson effectively re-launched enGene from a small private company working in the GI discovery
space into a clinical stage gene therapy oncology company trading on Nasdaq, implementing a new scientific, technical and strategic vision
for the Company. From August 2016 to November 2017, Mr. Hanson served as President and Chief Executive Officer of Ohana Biosciences,
a biotechnology company based in Cambridge, MA, and as member of the Ohana Board of Directors and consultant to Ohana from November 2017
to June 2018. Mr. Hanson previously served as Executive Vice President and Chief Strategy Officer for NuVasive, Inc. from November 2015
to August 2016. Mr. Hanson served as Corporate Vice President of General Electric Company and member of the senior executive team of
GE Healthcare, a global pharmaceutical, medical device and healthcare services business from May 2014 to October 2015. In January 2013,
Mr. Hanson served as Company Group Chairman and Executive Vice President of Valeant Pharmaceuticals International, Inc. (now Bausch Health
Companies Inc.). Previously, he served in various roles at Medicis Pharmaceutical Corporation, including as Executive Vice President
and Chief Operating Officer between July 2006 and December 2012. Mr. Hanson also served in numerous roles at GE Healthcare, including
General Counsel roles, from April 1999 to July 2006. Mr. Hanson holds a B.S. from Cornell University and a J.D. from Duke University
School of Law. We believe that Mr. Hanson is qualified to serve as a member of our board of directors because of his extensive professional
experience in science and biotechnology companies.

Board
Diversity

The
table below provides certain information regarding the diversity of our board of directors as of the date of this annual report.

 33 

    Board
    Diversity Matrix
  
    Country of
    Principal Executive Officers:
    United States
  
    Foreign Private Issuer
    No
  
    Disclosure Prohibited under
    Home Country Law
    N/A
  
    Total Number of Directors
    4

    Female
     
    Male
     
    Non-Binary
     
    Did
    Not Disclose Gender
  
    Part I: Gender Identity

    Directors
     
    0
     
    4
     
    0
     
    0
  
    Part II: Demographic
    Background